Rankings
▼
Calendar
INMB FY 2020 Earnings — INmune Bio, Inc. Revenue & Financial Results | Market Cap Arena
INMB
INmune Bio, Inc.
$37M
FY 2020 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$11,000
Gross Profit
$11,000
100.0% margin
Operating Income
-$12M
-111163.6% margin
Net Income
-$12M
-109990.9% margin
EPS (Diluted)
$-1.01
Cash Flow
Operating Cash Flow
-$9M
Free Cash Flow
-$9M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$41M
Total Liabilities
$2M
Stockholders' Equity
$39M
Cash & Equivalents
$22M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$11,000
$0
—
Gross Profit
$11,000
$0
—
Operating Income
-$12M
-$8M
-57.7%
Net Income
-$12M
-$8M
-57.6%
← Q4 2019
All Quarters
Q1 2020 →